{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:55:21Z","timestamp":1787313321126,"version":"build-2736575974"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.waojou.2023.100856","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T19:31:19Z","timestamp":1704223879000},"page":"100856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antibiotic prophylaxis in immunosuppressed patients \u2013 Missed opportunities from trimethoprim-sulfamethoxazole allergy label"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8228-446X","authenticated-orcid":false,"given":"Wei-I","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Hissaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.waojou.2023.100856_bib1","first-page":"CD005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim-sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.waojou.2023.100856_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/j.1875-9114.1981.tb03548.x","article-title":"Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications","volume":"1","author":"Gleckman","year":"1981","journal-title":"Pharmacotherapy"},{"issue":"12b","key":"10.1016\/j.waojou.2023.100856_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","article-title":"Overview of infections in the immunocompromised host","volume":"4","author":"Dropulic","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-199921020-00003","article-title":"Drug-induced lymphopenia: focus on CD4+ and CD8+ cells","volume":"21","author":"Gergely","year":"1999","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib7","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.waojou.2023.100856_bib9","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work","year":"2009","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib10","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","volume":"48","author":"Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00042560-199706010-00002","article-title":"Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients","volume":"15","author":"Bucher","year":"1997","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"12","key":"10.1016\/j.waojou.2023.100856_bib13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1097\/00002030-199512000-00007","article-title":"Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis","volume":"9","author":"Antinori","year":"1995","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.waojou.2023.100856_bib14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1702004","article-title":"A\u00a0prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim\/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation","volume":"24","author":"Colby","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.waojou.2023.100856_bib15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","author":"Hughes","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.waojou.2023.100856_bib16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199212243272604","article-title":"A\u00a0controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021","volume":"327","author":"Hardy","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.waojou.2023.100856_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/jcp.44.10.820","article-title":"Disseminated pneumocystis carinii infection in AIDS","volume":"44","author":"Coker","year":"1991","journal-title":"J\u00a0Clin Pathol"},{"issue":"26","key":"10.1016\/j.waojou.2023.100856_bib18","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","article-title":"A\u00a0controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group","volume":"327","author":"Schneider","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.waojou.2023.100856_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cmi.2016.04.025","article-title":"A\u00a0matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication","volume":"22","author":"Conrad","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000380757","article-title":"Atovaquone for prophylaxis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation","volume":"134","author":"Mendorf","year":"2015","journal-title":"Acta Haematol"},{"key":"10.1016\/j.waojou.2023.100856_bib21","unstructured":"Care P-AGDoHaA. TRIMETHOPRIM\u00a0+ SULFAMETHOXAZOLE. https:\/\/www.pbs.gov.au\/medicine\/item\/2951h-3103h-3390k-3391l. Accessed 30.March.2023."},{"key":"10.1016\/j.waojou.2023.100856_bib22","unstructured":"Care P-AGDoHaA. ATOVAQUONE. https:\/\/www.pbs.gov.au\/medicine\/item\/8300W. Accessed 30.March.2023."},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib23","first-page":"248","article-title":"Usage and cost of a nebulised pentamidine clinic in a large teaching hospital","volume":"58","author":"Ward","year":"2009","journal-title":"J\u00a0Infect"},{"issue":"15","key":"10.1016\/j.waojou.2023.100856_bib24","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/clinids\/4.2.426","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients","volume":"4","author":"Jick","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/00002030-199209000-00024","article-title":"Patient tolerance of nebulized pentamidine or cotrimoxazole as secondary prophylaxis for Pneumocystis carinii pneumonia","volume":"6","author":"Smith","year":"1992","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.1978.tb05807.x","article-title":"Trimethoprim and sulphamethoxazole inhibition of haematopoiesis in\u00a0vitro","volume":"40","author":"Golde","year":"1978","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1651-2227.1984.tb17772.x","article-title":"Early and late neutropenia in children treated with cotrimoxazole (trimethoprim-sulfamethoxazole)","volume":"73","author":"Principi","year":"1984","journal-title":"Acta Paediatr Scand"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib29","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/bmt.2010.285","article-title":"Cotrimoxazole myelotoxicity in hematopoietic SCT recipients: time for reappraisal","volume":"46","author":"Fontanet","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.waojou.2023.100856_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18773\/austprescr.2008.006","article-title":"'Sulfur allergy' label is misleading","volume":"31","author":"Smith","year":"2008","journal-title":"Aust Prescr"},{"issue":"1","key":"10.1016\/j.waojou.2023.100856_bib31","first-page":"82","article-title":"Anaphylaxis to trimethoprim: an under-appreciated risk in acute medical care","volume":"16","author":"Nordstrand","year":"2004","journal-title":"Emerg Med Australasia (EMA)"},{"issue":"7","key":"10.1016\/j.waojou.2023.100856_bib32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1034\/j.1398-9995.1999.00210.x","article-title":"Anaphylaxis to trimethoprim","volume":"54","author":"Alfaya","year":"1999","journal-title":"Allergy"},{"issue":"1 Pt 1","key":"10.1016\/j.waojou.2023.100856_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0091-6749(96)70295-6","article-title":"Anaphylaxis to trimethoprim","volume":"97","author":"Cabanas","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib34","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1365-2222.1998.00258.x","article-title":"Anaphylactic reactions associated with trimethoprim","volume":"28","author":"Bijl","year":"1998","journal-title":"Clin Exp Allergy"},{"issue":"4 Pt 1","key":"10.1016\/j.waojou.2023.100856_bib35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1398-9995.1992.tb02067.x","article-title":"Hypersensitivity to trimethoprim","volume":"47","author":"Alonso","year":"1992","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.1987.tb05819.x","article-title":"Trimethoprim associated fixed drug eruption","volume":"116","author":"Hughes","year":"1987","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.1998.tb02395.x","article-title":"Generalized erythematous skin eruptions due to trimethoprim itself and co-trimoxazole","volume":"25","author":"Hattori","year":"1998","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100856_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jaip.2019.08.019","article-title":"Fixed drug eruption of the tongue due to trimethoprim-sulfamethoxazole","volume":"8","author":"Gleeson","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2023.100856_bib39","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1100\/tsw.2006.361","article-title":"Fixed drug eruption of the penis secondary to sulfamethoxazole-trimethoprim","volume":"6","author":"Lawrentschuk","year":"2006","journal-title":"Sci World J"},{"issue":"1 Pt 1","key":"10.1016\/j.waojou.2023.100856_bib40","first-page":"41","article-title":"Fixed drug eruption of the penis due to co-trimoxazole","volume":"21","author":"Amir","year":"1987","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.waojou.2023.100856_bib41","article-title":"A\u00a0case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole","volume":"2014","author":"Rijal","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1345\/aph.10310","article-title":"Trimethoprim\/sulfamethoxazole-induced toxic epidermal necrolysis","volume":"35","author":"See","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4103\/0253-7613.99346","article-title":"Trimethoprim-sulfamethoxazole-induced steven Johnson syndrome in an HIV-infected patient","volume":"44","author":"Taqi","year":"2012","journal-title":"Indian J Pharmacol"},{"issue":"10","key":"10.1016\/j.waojou.2023.100856_bib44","first-page":"1043","article-title":"Trimethoprim-sulfamethoxazole-induced drug eruption with eosinophilia and systemic symptoms (DRESS)","volume":"16","author":"Antia","year":"2017","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.anai.2015.12.009","article-title":"Trimethoprim-sulfamethoxazole-induced DRESS syndrome in a 4-year-old child","volume":"116","author":"Rueda-Valencia Mde","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib46","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"issue":"24","key":"10.1016\/j.waojou.2023.100856_bib47","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.waojou.2023.100856_bib48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.anai.2014.08.006","article-title":"Trimethoprim-sulfamethoxazole-induced aseptic meningitis-not just another sulfa allergy","volume":"113","author":"Bruner","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib49","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaip.2019.07.003","article-title":"Oral challenge with trimethoprim-sulfamethoxazole in patients with \u201csulfa\u201d antibiotic allergy","volume":"8","author":"Krantz","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.waojou.2023.100856_bib50","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jaip.2019.05.051","article-title":"Beta-lactam and sulfonamide allergy testing should Be a standard of care in immunocompromised hosts","volume":"7","author":"Trubiano","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2222.1987.tb02005.x","article-title":"An immunoassay for the detection of IgE antibodies to trimethoprim in the sera of allergic patients","volume":"17","author":"Harle","year":"1987","journal-title":"Clin Allergy"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1398-9995.1988.tb00417.x","article-title":"Drugs as allergens. The molecular basis of IgE binding to trimethoprim","volume":"43","author":"Smal","year":"1988","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.waojou.2023.100856_bib53","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0161-5890(88)90050-8","article-title":"Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole","volume":"25","author":"Harle","year":"1988","journal-title":"Mol Immunol"},{"key":"10.1016\/j.waojou.2023.100856_bib54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tox.2016.08.010","article-title":"Immunogenicity of trimethoprim\/sulfamethoxazole in a macaque model of HIV infection","volume":"368\u2013369","author":"Wong","year":"2016","journal-title":"Toxicology"},{"issue":"1-4","key":"10.1016\/j.waojou.2023.100856_bib55","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000235372","article-title":"Evaluation of immune parameters in HIV+ subjects reporting adverse reactions to sulfamethoxazole","volume":"94","author":"O'Neil","year":"1991","journal-title":"Int Arch Allergy Appl Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib56","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0091-6749(03)01783-4","article-title":"Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics","volume":"112","author":"Empedrad","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200326030-00004","article-title":"Safety of celecoxib in individuals allergic to sulfonamide: a pilot study","volume":"26","author":"Shapiro","year":"2003","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.0105-1873.2004.00274.x","article-title":"Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing","volume":"51","author":"Tornero","year":"2004","journal-title":"Contact Dermatitis"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0536.1999.tb06127.x","article-title":"Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption","volume":"41","author":"Ozkaya-Bayazit","year":"1999","journal-title":"Contact Dermatitis"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib60","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archderm.139.9.1181","article-title":"A\u00a0systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis","volume":"139","author":"Mashiah","year":"2003","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib61","first-page":"781","article-title":"Reactivation of skin lesions after patch testing to investigate drug rash with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"107","author":"Cordoba","year":"2016","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib62","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A\u00a0multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100856_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","article-title":"Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)","volume":"62","author":"Santiago","year":"2010","journal-title":"Contact Dermatitis"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0536.1996.tb02364.x","article-title":"Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Wolkenstein","year":"1996","journal-title":"Contact Dermatitis"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib65","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000358491","article-title":"Enhancement of drug-specific lymphocyte proliferation using CD25(hi)-depleted CD3(+) effector cells","volume":"163","author":"Srinoulprasert","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib66","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jdermsci.2017.03.007","article-title":"Novel interferon-gamma enzyme-linked immunoSpot assay using activated cells for identifying hypersensitivity-inducing drug culprits","volume":"86","author":"Kato","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"issue":"9","key":"10.1016\/j.waojou.2023.100856_bib67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cea.12145","article-title":"In\u00a0vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test","volume":"43","author":"Porebski","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib68","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/WOX.0b013e3181778282","article-title":"The p-i concept: pharmacological interaction of drugs with immune receptors","volume":"1","author":"Pichler","year":"2008","journal-title":"World Allergy Organ J"},{"issue":"5","key":"10.1016\/j.waojou.2023.100856_bib69","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/mol.62.5.1011","article-title":"Haptenation of sulfonamide reactive metabolites to cellular proteins","volume":"62","author":"Manchanda","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.waojou.2023.100856_bib70","first-page":"900","article-title":"Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity","volume":"19","author":"Cribb","year":"1991","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.waojou.2023.100856_bib71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00204-010-0530-z","article-title":"Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine","volume":"84","author":"Bhusari","year":"2010","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib72","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2009.10.031","article-title":"Stimulation of human T cells with sulfonamides and sulfonamide metabolites","volume":"125","author":"Castrejon","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00002030-199403000-00006","article-title":"Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients","volume":"8","author":"Carr","year":"1994","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.waojou.2023.100856_bib74","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00126334-200408150-00007","article-title":"Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole-nitroso in HIV infection","volume":"36","author":"Trepanier","year":"2004","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib75","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2125.2010.03889.x","article-title":"Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis","volume":"71","author":"Abouraya","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.coph.2007.04.005","article-title":"N-Acetylcysteine--a safe antidote for cysteine\/glutathione deficiency","volume":"7","author":"Atkuri","year":"2007","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib77","first-page":"143","article-title":"N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients","volume":"35","author":"Akerlund","year":"1997","journal-title":"J\u00a0Infect"},{"issue":"5","key":"10.1016\/j.waojou.2023.100856_bib78","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00042560-199812150-00009","article-title":"A\u00a0randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group","volume":"19","author":"Walmsley","year":"1998","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"10","key":"10.1016\/j.waojou.2023.100856_bib79","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/FPC.0b013e328357a735","article-title":"Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity","volume":"22","author":"Sacco","year":"2012","journal-title":"Pharmacogenetics Genom"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156000","article-title":"Genome-wide association study in immunocompetent patients with delayed hypersensitivity to sulfonamide antimicrobials","volume":"11","author":"Reinhart","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib81","article-title":"Sulfonamide allergies","volume":"7","author":"Giles","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000312632","article-title":"Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole","volume":"153","author":"Zawodniak","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"10.1016\/j.waojou.2023.100856_bib83","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0149-2918(00)87238-0","article-title":"Immunologic tolerability profile of celecoxib","volume":"21","author":"Patterson","year":"1999","journal-title":"Clin Therapeut"},{"issue":"17","key":"10.1016\/j.waojou.2023.100856_bib84","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa022963","article-title":"Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics","volume":"349","author":"Strom","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.waojou.2023.100856_bib85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jama.2017.6510","article-title":"Penicillin allergy is not necessarily forever","volume":"318","author":"Trubiano","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.waojou.2023.100856_bib86","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamainternmed.2020.0403","article-title":"Development and validation of a penicillin allergy clinical decision rule","volume":"180","author":"Trubiano","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.waojou.2023.100856_bib87","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1016\/j.jaip.2021.05.046","article-title":"The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy","volume":"9","author":"Rose","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.waojou.2023.100856_bib88","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00002030-199301000-00010","article-title":"Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients","volume":"7","author":"Carr","year":"1993","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib89","first-page":"CD005646","article-title":"Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV\/AIDS in patients\u00a0with previous history of hypersensitivity to cotrimoxazole","author":"Lin","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib90","first-page":"111","article-title":"Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction?","volume":"38","author":"Gompels","year":"1999","journal-title":"J\u00a0Infect"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib91","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/clinids\/20.4.849","article-title":"Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ","volume":"20","author":"Gluckstein","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib92","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00002030-199506000-00007","article-title":"Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients","volume":"9","author":"Nguyen","year":"1995","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.waojou.2023.100856_bib93","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.1997.03890400065009","article-title":"Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus","volume":"133","author":"Caumes","year":"1997","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.waojou.2023.100856_bib94","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/323353","article-title":"Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ","volume":"184","author":"Leoung","year":"2001","journal-title":"J\u00a0Infect Dis"},{"issue":"6 Pt 1","key":"10.1016\/j.waojou.2023.100856_bib95","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0091-6749(98)70343-4","article-title":"Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients","volume":"102","author":"Demoly","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.waojou.2023.100856_bib96","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.waojou.2023.100856_bib97","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity - a consensus statement","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib98","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1086\/516995","article-title":"Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulfamethoxazole","volume":"25","author":"Douglas","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.waojou.2023.100856_bib99","article-title":"Automation of penicillin adverse drug reaction categorisation and risk stratification with machine learning natural language processing","volume":"156","author":"Inglis","year":"2021","journal-title":"Internet J Med Inf"},{"issue":"2","key":"10.1016\/j.waojou.2023.100856_bib100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002030-199202000-00004","article-title":"Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS","volume":"6","author":"Carr","year":"1992","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib101","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/j.1875-9114.1996.tb03029.x","article-title":"Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia","volume":"16","author":"Warnock","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib102","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/archinte.1992.00400150053009","article-title":"A\u00a0comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients","volume":"152","author":"Martin","year":"1992","journal-title":"Arch Intern Med"},{"issue":"21","key":"10.1016\/j.waojou.2023.100856_bib103","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJM199305273282102","article-title":"Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group","volume":"328","author":"Girard","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.waojou.2023.100856_bib104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1081-1206(10)62474-X","article-title":"A\u00a05-day course of oral desensitization to trimethoprim\/sulfamethoxazole (T\/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T\/S","volume":"85","author":"Yoshizawa","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.waojou.2023.100856_bib105","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0091-6749(94)70048-6","article-title":"Desensitization to trimethoprim\/sulfamethoxazole in HIV-infected patients","volume":"93","author":"Absar","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T13:37:13Z","timestamp":1724765833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455123001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1939455123001163"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100856","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic prophylaxis in immunosuppressed patients \u2013 Missed opportunities from trimethoprim-sulfamethoxazole allergy label","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100856"}}